Clinical trials: Naloxone
Opioid Overdose, Drug Overdose
Preventing Overdose Using Information and Data From the Environment
The objectives of this project are to leverage surveillance data to predict future overdose outbreaks, and to evaluate the impact of a randomized, statewide, community-level intervention trial to target overdose prevention…
- Trial name
- PROVIDENT (NCT05096429)
- Testing
- PROVIDENT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Brown University
Opioid-Related Disorders, Opiate Dependence
Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)
The aim of this post marketing surveillance study is to investigate the retention rate after 12 months of drug dependence treatment with SUBOXONE® (buprenorphine plus naloxone) of opioid dependent patients under real life…
- Conditions
- Opioid-Related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00723749
- Testing
- Buprenorphine/Naloxone
- Volunteers
- 384 people
- Sponsor
- Indivior Inc.
Postoperative Nausea and Vomiting
Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia
Postoperative nausea and vomiting (PONV) is one of the most undesirable complications after general anesthesia, and may lead to increased hospital stay and health care costs.
- Trial name
- NCT02416115
- Testing
- Ramosetron, Naloxone, saline
- Volunteers
- 90 people
- Sponsor
- Kyungpook National University Hospital
Drug Overdose
Nasal Naloxone for Narcotic Overdose
The goal of this study is to determine if nasal naloxone is inferior to standard care for naloxone administration in a pre-hospital setting.
- Trial name
- NCT01912573
- Testing
- Intranasal (IN) naloxone, Intravenous (IV) naloxone, Intramuscular (IM) naloxone
- Where
- 3 sites in United States
- Volunteers
- 236 people
- Sponsor
- Judith Feinberg
Heroin Dependence, Morphine Dependence
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.
- Conditions
- Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00032968
- Testing
- Buprenorphine/naloxone
- Where
- 7 sites in United States
- Volunteers
- 341 people
- Sponsor
- University of California, Los Angeles
Opioid Use
Incentivizing Buprenorphine-Naloxone Initiation in Emergency Departments
This study seeks to test standard and behavioral economic-enhanced training strategies to bolster first-time Emergency Department-initiated buprenorphine-naloxone administration among Emergency Department providers.
- Trial name
- NCT03821103
- Testing
- Training, Behavioral economic enhanced arm
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Pennsylvania
Overdose
A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk
Adolescent (ages 10-19) overdose deaths are the third leading cause of pediatric death and continue to rise in the United States.
- Trial name
- NCT07022717
- Testing
- Brief youth overdose prevention education, Information about Naloxone, Usual standard of care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Boston Medical Center
Opioid Use Disorder (OUD)
HEALing Communities Study
This study will test the impact of implementing the Communities That Helping to End Addiction Long-term (HEAL) intervention on opioid overdose deaths within 67 highly affected communities with the goal of reducing opioid overdose…
- Trial name
- NCT04111939
- Testing
- Communities That HEAL, Wait-list control
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- RTI International
Carrying Naloxone/Narcan on Their Person or in Their Vehicle, Being Trained to Respond to an Opioid Overdose
The Feasibility of Using the PulsePoint to Facilitate Overdose Education and Naloxone Distribution
This study is a feasibility trial to assess whether, in a random sample of 180 agencies where PulsePoint is already active, revised procedures (hereinafter PulsePoint-OD) to facilitate opioid overdose and naloxone distribution…
- Trial name
- PP-OD (NCT06523985)
- Testing
- Push messages (standard), Push messages (customized)
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Indiana University
Harm Reduction, Naloxone
Vending Machine Naloxone Distribution for Your Community (VENDY)
Vending machines are an innovative strategy shown to increase access to naloxone, a medication used to reverse opioid overdose. The aim of this proposal is to study the reach of a community-initiated, stakeholder engaged…
- Conditions
- Harm Reduction, Naloxone, Opioid Overdose
- Trial name
- NCT06429436
- Testing
- VENDY
- Where
- 3 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- University of Colorado, Denver
Opioid-Related Disorders
Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1
The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.
- Trial name
- NCT00078117
- Testing
- Buprenorphine
- Where
- 11 sites in United States
- Volunteers
- 516 people
- Sponsor
- University of California, Los Angeles
Opiate Addiction
Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents
This study is designed to determine the relative effectiveness of buprenorphine/naloxone (Suboxone) pharmacotherapy versus naltrexone pharmacotherapy for treatment retention, relapse prevention and opioid craving reduction among…
- Trial name
- NCT01015066
- Testing
- Buprenorphine/naloxone, Naltrexone
- Where
- United States
- Sponsor
- State University of New York at Buffalo
Heroin Dependence, Morphine Dependence
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.
- Conditions
- Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00032955
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in United States
- Volunteers
- 163 people
- Sponsor
- University of California, Los Angeles
Opiate Dependence
Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice
The CS 1018 study will recruit a total of 600 patients seeking treatment for opiate dependence. They will be recruited from six states (Florida, New York, Texas, California, Washington, and Illinois), with up to ten private…
- Trial name
- NCT00007527
- Testing
- naloxone, buprenorphine
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- US Department of Veterans Affairs
Brain Death, Organ Donors
Naloxone for Optimizing Hypoxemia Of Lung Donors
Brain-dead patients who provide authorization for organ donation will be randomized to naloxone or placebo if baseline arterial blood gas (ABG) after initiation of OPO (Organ Procurement Organization) management reveals…
- Conditions
- Brain Death, Organ Donors, Lung Transplantation
- Trial name
- NO-HOLDS (NCT02581111)
- Testing
- Naloxone, Normal saline
- Where
- 4 sites in United States
- Volunteers
- 199 people
- Sponsor
- Washington University School of Medicine
Morphinan Opioid Overdose
Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose
The purpose of this study is to determine which route of administration is better for treatment of opioid overdosed patients
- Trial name
- NCT01293058
- Testing
- Intranasal naloxone, Intravenous
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Gambling, Opioid
Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray
Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. Brief intervention.
- Conditions
- Gambling, Opioid, Naloxone, Spray
- Trial name
- NALPILO (NCT03223896)
- Testing
- Naloxone hydrochloride 20mg/ml
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Pruritus
Naloxone for the Treatment of Opioid-Induced Pruritus
The purpose of this study is to improve how we treat itching, a common side effect associated with the use of morphine pain medication.
- Trial name
- NCT01071057
- Testing
- Naloxone, Saline/Morphine
- Where
- Canada
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Opioid-Related Disorders, Opiate Dependence
Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)
The purpose of this study is to evaluate the acceptability and safety of switching to Suboxone® (buprenorphine plus naloxone) and the effect of the switch on medication dispensing.
- Conditions
- Opioid-Related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00725608
- Testing
- buprenorphine/naloxone
- Where
- Austria
- Volunteers
- 339 people
- Sponsor
- Indivior Inc.
Opioid Induced Respiratory Depression
Critical Respiratory Events in Children Requiring Naloxone: Naloxone Use as Opioid Safety Measure
Opioids are the mainstay of analgesia in hospitalized children but opioid therapy is associated with life-threatening respiratory depression requiring antagonism with naloxone.
- Trial name
- NCT01860885
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati